Serious adverse events · premenopausal women (age 18−47.3 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total hip BMD · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lumbar spine bone mineral density (BMD) · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pain Scale from: 0 to 10, 0 is no pain. · people with osteoporotic vertebral compression fracture
1 finding from 1 review
Intervention not reported
Disability (Roland‐Morris Disability Questionnaire) Scale from: 0 to 23; 0 is no disability. · people with osteoporotic vertebral compression fracture
1 finding from 1 review
Intervention not reported
Disease‐specific quality of Life (QUALEFFO) Scale from: 0 to 100; 0 is best. · people with osteoporotic vertebral compression fracture
1 finding from 1 review
Intervention not reported
Overall quality of Life (EQ5D) Scale from: 0 to 1; 1 is best. · people with osteoporotic vertebral compression fracture
1 finding from 1 review
Intervention not reported
Participant global assessment of success (People perceived their pain as better) · people with osteoporotic vertebral compression fracture
The intervention showed no clear difference in participant global assessment of success (People perceived their… (moderate certainty).
1 finding from 1 review
Intervention not reported
Incident symptomatic vertebral fractures · people with osteoporotic vertebral compression fracture
The intervention showed no clear difference in incident symptomatic vertebral fractures (low certainty).
1 finding from 1 review
Intervention not reported
Other serious adverse events · people with osteoporotic vertebral compression fracture
The intervention showed no clear difference in other serious adverse events (low certainty).
1 finding from 1 review
Response to treatment (20% improvement)* · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes response to treatment (20% improvement)* compared with methylprednisolone (very low certainty).
1 finding from 1 review
Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).
1 finding from 1 review
Adverse events ‐ Death · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Death compared with methylprednisolone (very low certainty).
1 finding from 1 review
SLICC scores (damage index) Scale: from 0 to 48 (lower is better) · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Disease activity · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Seizures · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes seizures compared with methylprednisolone (very low certainty).
1 finding from 1 review
Intervention not reported
Total number of fractures radiographs · preventing and treating osteoporosis in postmenopausal women
The intervention showed no clear difference in total number of fractures radiographs (high certainty).
1 finding from 1 review
Intervention not reported
Bone mineral density % change: spine · preventing and treating osteoporosis in postmenopausal women
1 finding from 1 review
Intervention not reported
Bone mineral density % change: femoral neck · preventing and treating osteoporosis in postmenopausal women
1 finding from 1 review
Intervention not reported
Bone mineral density % change: total hip · preventing and treating osteoporosis in postmenopausal women
1 finding from 1 review